Clinical Trials Logo

Clinical Trial Summary

This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph nodes. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as antiandrogen therapy may lessen the amount of androgen made by the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if antiandrogen therapy is more effective with or without axitinib before surgery in treating patients with prostate cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To compare the proportion of patients progression-free one year after treatment with axitinib plus androgen deprivation versus (vs.) androgen deprivation therapy alone and surgery in newly diagnosed prostate cancer patients with lymph node metastases (TxN1M0 or TxNxM1a) or clinical suspicion of lymph node metastases. SECONDARY OBJECTIVES: I. To compare the rate of pathologic complete response (pCR) in the primary tumor. II. To evaluate time to progression. III. Describe the perioperative and postoperative morbidity of pre-surgical treatment. IV. Evaluate the effects of a 6-month time course of androgen deprivation with or without axitinib in prostate cancer tissue and blood. V. Develop a prospective tissue archive of prostate tumors that have metastasized to lymph nodes. OUTLINE: Patients receive antiandrogen therapy per standard care for 8 weeks. Patients are then randomized to 1 of 2 treatment arms. ARM I: Patients receive antiandrogen therapy per standard care and axitinib orally (PO) twice daily (BID) for 4 months. Patients then undergo radical prostatectomy and pelvic lymph node dissection. ARM II: Patients receive antiandrogen therapy per standard care for 4 months and then undergo radical prostatectomy and pelvic lymph node dissection. After completion of study treatment, patients are followed up at 1 and 3 months, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then yearly thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01409200
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 26, 2012
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Terminated NCT02215161 - Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT02703623 - Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT02849990 - A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy Phase 2
Completed NCT03456804 - ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer Phase 2
Recruiting NCT03456843 - Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer Phase 2
Completed NCT03406858 - Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Phase 2
Active, not recruiting NCT00544830 - Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Phase 2
Active, not recruiting NCT02099864 - Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Phase 2
Active, not recruiting NCT03503344 - Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT03442556 - Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Phase 2
Active, not recruiting NCT02893917 - Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer Phase 2
Active, not recruiting NCT03419234 - Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Phase 2